Skip to main content
HLF logo

HLF · Herbalife Ltd.

Track HLF — free
$15.57 +0.00 (+0.00%)
Market Cap
$1.63B
Shares
104.90M
Volume · Nov 19 973.02K Avg daily vol (3M) 1.57M

Price & Indicators

 

Key stats

Close
$15.57
Open
$15.92
Day range
$15.52–16.19
52-week closing range
$9.22–19.96
Average volume, 30 days
1.6M
Short interest
7.5M · 7.1% of shares · 5.2 days
Short volume, last session
64%
Last earnings
Nov 2, 2026
Latest filing
10-Q · Nov 2
Price history
Jan 2020 to Nov 2026

Up next

Feb 17, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 2
Earnings call
Net sales up 6% to $1.4 billion; full-year guidance raised

Herbalife's third-quarter net sales rose 6% to $1.4 billion, with adjusted EBITDA of $182 million and a 13.5% margin. The company raised its full-year reported net sales growth outlook to 4.9% to 5.9%.

5 source passages
Third quarter net sales were $1.4 billion, up 6% versus the third quarter of 2025 Adjusted EBITDA was $182 million, also above our guidance range of $160 million to $180 million. An adjusted EBITDA margin was 13.5%, up 70 basis points year-over-year. For the full year, we have raised our net sales guidance on both a reported and constant currency basis. We now expect reported net sales to increase 4.9% to 5.9% year-over-year Open the document at this passage
Nov 2
Current report 8-K
Sales rise 6.0% as adjusted EBITDA reaches $182.4 million

Herbalife reported third-quarter net sales of $1.35 billion, up 6.0%, and adjusted EBITDA of $182.4 million. Year-to-date operating cash flow reached $298.0 million, and a share repurchase program of up to $250 million over three years was authorized.

Financial results, Regulation FD disclosure
4 source passages
Herbalife reported third quarter 2026 net sales of $1.35 billion, up 6.0% year-over-year, including 160 basis points of foreign currency (“FX”) headwinds, and primarily driven by increased sales volume. Adjusted EBITDA^1^ of $182.4 million includes approximately $11.3 million of FX headwinds year-over-year, with adjusted EBITDA^1^ margin of 13.5%, up 70 basis points versus the third quarter of 2025. Year-to-date net cash provided by operating activities of $298.0 million; capital expenditures of $40.7 million Board authorized new share repurchase program of up to $250 million over three years Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month net income falls 33.9% to $94.4 million

Herbalife's nine-month net income fell 33.9% to $94.4 million, mainly due to a $94.6 million loss on debt extinguishment, while net sales rose 6.4% to $3,994.2 million.

Revenue $1.35B ▲ 6.0% Net income $58.8M ▲ 36.1% Diluted EPS $0.55 ▲ 31.0%
Read from the MD&A section
5 source passages
Net income attributable to Herbalife was $58.8 million, or $0.55 per diluted share, and $94.4 million, or $0.88 per diluted share, for the three and nine months ended September 30, 2026, respectively. Net income attributable to Herbalife increased $15.6 million, or 36.1%, and decreased $48.5 million, or 33.9%, for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025. The decrease in net income attributable to Herbalife for the nine months ended September 30, 2026 was mainly due to $94.6 million of loss on extinguishment of debt related to our April 2026 debt refinancing Net sales were $1,350.2 million and $3,994.2 million for the three and nine months ended September 30, 2026, respectively. Net sales increased $76.5 million, or 6.0%, and $239.7 million, or 6.4%, for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.28B
Trailing 12 months
Net income (TTM)
$179.80M
Trailing 12 months
Revenue growth YoY
+6.0%
Year over year
Operating margin
9.6%
Trailing 12 months
P / E (TTM)
9.3
Trailing earnings · reciprocal yield 10.8%
FCF yield
20.6%
TTM · current market cap
Return on invested capital
32.8%
Trailing 12 months
Net cash
−$1.52B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.2%
Year over year · more shares
Price change (1Y)
+68.9%
Trailing year
Short interest
7.1%
Latest settlement · 5.2 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Herbalife delivered fourth consecutive quarter of net sales growth, beating constant-currency guidance, while narrowing full-year guidance and raising constant-currency adjusted EBITDA midpoint; however, a $94.6M loss on debt extinguishment drove a GAAP net loss of $26.3M and diluted loss per share of $(0.25).

Bullish
  • + Net sales of $1.3B, up 5.4% YoY, at top of guidance; constant-currency growth of 5.8% exceeded guidance by ~80 bps
  • + Full-year 2026 adjusted EBITDA constant-currency midpoint raised; range tightened
  • + Full-year 2026 net sales guidance range narrowed with midpoint raised
Bearish
  • − Adjusted effective tax rate jumped to 43.2% from 27.7%, a ~$0.14 unfavorable impact to adjusted diluted EPS; full-year adjusted tax rate now ~35%
  • − Gross profit margin declined 30 bps YoY to 77.7% on country mix and higher costs
  • − FX was a headwind: 40 bps drag on reported net sales, ~$8M drag on adjusted EBITDA, and reported full-year adjusted EBITDA midpoint lowered
  • − EMEA net sales declined 3.5% reported / 5.6% constant currency on 12% volume decline
  • − China net sales declined 24.5% reported / 29% constant currency on 29% volume decline

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +15%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 59%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +31%
trailing
YTD return +21%
this year
Relative strength +36%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $14 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +40 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.14% of shares out · ▼ -6.3% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
252 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
Gross margin 78%
contracting
EPS growth −12%
Y/Y
Free cash flow $252.9M
Valuation P/E 9.3
below peers
Buyback $250.0M
authorized
Balance sheet $1.6B
net debt
Quant / Vol
risk profile
Very High
Volatility 59%
annualized · 1-yr
Max drawdown −45%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 3
Latest guidance · from the 8-K filed Nov 2, 2026
Fourth Quarter 2026
Net Sales 0.5% – 4.5%
Net Sales Non-GAAP 2.5% – 6.5%
CapEx $13M – $23M
Full-Year 2026
Capitalized and prepaid SaaS implementation costs $35M – $45M
Adjusted effective tax rate^1^ Non-GAAP 35%
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA · Full-Year 2026 $675M – $705M
CapEx · Full-Year 2026 $50M – $80M
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
Adjusted EBITDA · third quarter, reported basis $160M – $180M
Capital expenditures · third quarter $15M – $25M
Guided vs delivered · last 3 settled
Reported diluted EPS the second quarter of 2021
guided $1.17 – $1.32
$1.31 In line
Reported diluted EPS full year 2021
guided $4.41 – $4.81
$4.13 Miss −10.4%
Reported diluted EPS first quarter 2021
guided $0.95 – $1.10
$1.33 Beat +29.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
59% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $14 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +40 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.14% of shares out · ▼ -6.3% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
252 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $16 · 59% Range high $20
vs 200-day avg +12% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA at constant currency non-GAAP $174.4M Q2 2026 —
China contribution margin $21.2M the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
Adjusted EBITDA $657.6M (non-GAAP)
+$8.5M Interest income
+$25.9M Inventory write-downs
+$44.1M Share-based compensation expenses
+$5.9M Other expenses (income)
= Credit Agreement EBITDA $742M
Inventory write-downs $3.5M Q2 2026 —
Net debt non-GAAP $1.67B Q2 2026 —
Net income margin -2% Six Months Ended June 30, 2026 —
Primary Reporting Segment contribution margin $543.3M the three months ended June 30, 2026 filing —
Primary Reporting Segment contribution margin percentage 42.9% the three months ended June 30, 2026 filing —
Share-based compensation expenses $10.4M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HLF
Herbalife Ltd.
this stock
$1.63B +20.8% +0.9% 9.3 7.1%
JBS
Jbs N.V.
$39.01B -17.8% — — 1.3%
KHC
Kraft Heinz Co
$29.50B +2.8% -0.1% — 8.7%
GIS
General Mills Inc
$18.44B -25.8% +4.1% — 7.0%
SJM
J M SMUCKER Co
$14.02B +34.2% +3.7% — 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
252
% held
97.4%
Net QoQ
-1.9M sh
Top holder
BAUPOST GROUP LLC/MA
Held Float
View
Held by Funds
Fund positions
84
View
Short & Settlement
Short Interest Falling
Shares short
7.5M
Days to cover
5.2d
Change
-501.2K sh
View
Short Volume
Short vol %
64%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
9.1K
Value
$108.1K
As of
Sep 21, 2026
View
Off-Exchange
Off-exchange %
40.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.0B
Net income (FY)
$228.3M
EPS diluted
$2.20
View
Buybacks
Authorized
$250.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 2, 2026
This year
18

Herbalife reported third-quarter net sales of $1.35 billion, up 6.0%, and adjusted EBITDA of $182.4 million. Year-to-date operating cash flow reached $298.0 million, and a share repurchase program of up to $250 million over three years was authorized.

View
Proposed Sales
Value
$123.2K
Shares
10.0K
Filed
May 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Herbalife to Participate in 1 on…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
HLF +2.4% +13.0% +30.8% +19.3% +20.8%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +7.8% +19.3% +36.5% +24.6% +15.8%

Capital returns

Buyback program · as of Nov 2, 2026
Authorized
$250.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1180262 CUSIP G4412G101 13F (30d) 260 filings 239 filers Visit website Investor relations